CyberKnife分次立体定向放疗脑转移瘤的放射性坏死风险与局部控制:八年单中心队列
该单中心回顾性队列纳入2016至2023年接受CyberKnife分次立体定向放疗的131例脑转移瘤患者共197个病灶,中位随访41.7个月。粗局部控制率为85.3%,放射性坏死发生于32.1%患者、症状性占14.5%;较大病灶与局部失败相关,较大病灶和既往手术是放射性坏死的独立预测因素。
要点
- 27 Gy/3次与30 Gy/5次是主要分割方案,粗局部控制率85.3%。
- 放射性坏死32.1%,症状性14.5%(2级11.4%、3级3.1%)。
- 较大病灶与局部失败及放射性坏死均相关,既往手术亦预测放射性坏死。
核心结论
- 分次立体定向放疗在该队列中实现持久局部控制,症状性放射性坏死率可接受。
- 肿瘤体积和既往手术与局部控制及放射性坏死均相关,支持基于病灶大小和临床背景的个体化剂量分割策略。
研究设计与样本
- 回顾性单中心研究,纳入2016年1月1日至2023年12月31日所有连续接受CyberKnife立体定向放疗的脑转移瘤患者。
- 共分析131例患者197个脑转移灶,中位随访41.7个月(范围1.7–207.8)。
- 局部控制和放射性坏死依据MRI按RANO-BM标准评估,放射性坏死按CTCAE v5.0分级。
主要发现
- 患者中位年龄63.4岁,肺癌为最常见原发(70.2%),68.8%为单发脑转移,70.2%在一线转移阶段接受治疗。
- 病灶水平上,52.3%接受27 Gy/3次,45.7%接受30 Gy/5次。
- 粗局部控制率85.3%,共29例局部失败;较大脑转移灶与局部失败显著相关(HR 1.03;95% CI 1.01–1.05;p=0.017)。
- 中位脑进展无生存期9.8个月(95% CI 7.4–13.6),脑进展与初始脑转移数目相关(HR 1.41;95% CI 1.10–1.8;p=0.006)。
- 放射性坏死发生于42例患者(32.1%),症状性占14.5%(2级11.4%、3级3.1%);较大病灶(HR 1.58;95% CI 1.04–2.49;p=0.048)和既往手术(HR 2.12;95% CI 1.05–4.33;p=0.037)是独立预测因素。
关键数值与推荐
- 局部控制和放射性坏死评估采用RANO-BM标准,放射性坏死分级采用CTCAE v5.0。
- 主要分割方案为27 Gy/3次(52.3%)和30 Gy/5次(45.7%)。
临床怎么用
- 对较大脑转移灶或术后瘤腔可考虑分次立体定向放疗以平衡局部控制与放射性坏死风险。
- 既往接受手术的患者应加强放射性坏死监测与鉴别。
- 剂量分割可依据病灶大小和临床背景个体化制定。
局限性
- 为回顾性单中心队列研究。
- 仍需进一步前瞻性数据以细化剂量约束并整合新兴治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic radiotherapy (SRT) is an effective treatment for patients with a limited number of brain metastases (BM). However, radionecrosis (RN) remains a concern, particularly in long-term survivors, as its distinction from tumor progression is challenging and may lead to inappropriate salvage strategies. Fractionated stereotactic radiotherapy (FSRT) has been proposed to improve the therapeutic ratio for larger lesions or postoperative cavities, but the optimal dose and fractionation remain uncertain. MATERIALS AND METHODS: We conducted a retrospective single-center study involving all consecutive patients who received SRT with CyberKnife® for BM between January 1, 2016, and December 31, 2023. Local control (LC) and RN were assessed on MRI according to RANO-BM criteria; RN was graded using CTCAE v5.0. RESULTS: A total of 131 patients with 197 BM were analyzed with a median follow-up of 41.7 months (range, 1.7–207.8). Median age was 63.4 years; lung cancer was the most common primary (70.2%). Most patients had a single BM (68.8%) and received treatment in the first-line metastatic setting (70.2%). At the lesion level (n = 197), most targets received 27 Gy in 3 fractions (52.3%) or 30 Gy in 5 fractions (45.7%). Crude LC was 85.3%, with 29 local failures. Larger BM was significantly associated with local failure (HR 1.03; 95% CI 1.01–1.05; p = 0.017). Median brain progression-free survival (bPFS) was 9.8 months (95% CI 7.4–13.6). Brain progression correlated with the initial number of BM (HR 1.41; 95% CI 1.10–1.8; p = 0.006). RN occurred in 42 patients (32.1%), symptomatic in 14.5% cases (11.4% grade 2, and 3.1% grade 3). Larger size of BM (HR 1.58; 95% CI 1.04–2.49; p = 0.048) and prior surgery (HR 2.12; 95% CI 1.05–4.33; p = 0.037) were independent predictors of RN. CONCLUSION: FSRT achieved durable LC with acceptable rates of symptomatic RN in this cohort. Tumor volume and prior surgery were associated with both LC and RN, supporting individualized dose–fractionation strategies based on lesion size and clinical context. Further prospective data are needed to refine dose constraints and integrate evolving therapies.
引用
- Alati A, Giraud P, Bibault JE, et al. Radionecrosis risk and local control after CyberKnife® fractionated stereotactic radiotherapy for brain metastases: an eight-year single-centre cohort. Radiat Oncol. 2026. PMID: 41918106. doi:10.1186/s13014-026-02824-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。